Lixisenatide: all 57 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced DiabetesEnrolling by invitationNCT07117240Phase 4
• iGlarLixi CGM Study in Chinese T2D Individuals After OADsRecruitingNCT06671587Phase 4
• The Effect of Lixisenatide on the Effect of Pituitary HormonesRecruitingNCT05804513Phase 4
• iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)CompletedNCT05413369Phase 3Results posted
• Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes MellitusCompletedNCT05114590Phase 4Results posted
• Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic AgentsTerminatedNCT03434119Phase 3Results posted
• Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension PeriodCompletedNCT02787551Phase 3Results posted
• Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal InsulinCompletedNCT02168491Phase 3Results posted
• Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 DiabetesCompletedNCT02058160Phase 3Results posted
• Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic PatientsCompletedNCT01798706Phase 3Results posted
• Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic PatientsCompletedNCT01768559Phase 3Results posted
• Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without MetforminCompletedNCT01596504Phase 2Results posted
• Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on MetforminCompletedNCT01517412Phase 3Results posted
• Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 DiabetesCompletedNCT01175473Phase 2Results posted
• Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by MetforminCompletedNCT01169779Phase 3Results posted
• Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)CompletedNCT01147250Phase 3Results posted
• 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 YearsCompletedNCT00976937Phase 3Results posted
• 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin GlargineCompletedNCT00975286Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)CompletedNCT00905255Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)CompletedNCT00866658Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of PioglitazoneCompletedNCT00763815Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of MetforminCompletedNCT00763451Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal InsulinCompletedNCT00715624Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of SulfonylureaCompletedNCT00713830Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of MetforminCompletedNCT00712673Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of MetforminCompletedNCT00707031Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in MonotherapyCompletedNCT00688701Phase 3Results posted
• Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver DiseaseActive, not recruitingNCT07274644Phase 4
• INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixiStatus unknownNCT04945070Phase 4
• Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 DiabetesStatus unknownNCT04893148Phase 4
• Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)CompletedNCT04196231Phase 4
• Effects of Insulin Glargine and Lixisenatide on the BrainTerminatedNCT03881995Phase 4
• Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal InsulinCompletedNCT03798080Phase 3
• Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)CompletedNCT03798054Phase 3
• Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)CompletedNCT03529123Phase 3
• Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's DiseaseCompletedNCT03439943Phase 2
• Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixiCompletedNCT03130426Phase 3
• Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During RamadanCompletedNCT02941367Phase 4
• A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)CompletedNCT02803918Phase 1
• Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 AnalogTerminatedNCT02767596Phase 4
• Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in JapanCompletedNCT02752828Phase 3
• Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic DrugsCompletedNCT02752412Phase 3
• Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in JapanCompletedNCT02749890Phase 3
• Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the BrainCompletedNCT02745470Not applicable
• The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised SubjectsCompletedNCT02640118Not applicable
• Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy PeopleStatus unknownNCT02308254Phase 1/2
• Effect of LIXIsenatide on the Renal SystemCompletedNCT02276196Phase 4
• Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic PatientsTerminatedNCT02274740Phase 2
• Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid SecretionTerminatedNCT02231658Phase 1
• Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin GlargineCompletedNCT02200991Phase 4
• Study on Lixisenatide and Counterregulation to HypoglycemiaCompletedNCT02020629Phase 4
• Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 DiabetesCompletedNCT01960179Phase 3
• Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- MetforminCompletedNCT01632163Phase 3
• Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 DiabetesCompletedNCT01572649Phase 1
• Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1CompletedNCT01146678Phase 1
• Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2CompletedNCT00931372Phase 1
• Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes MellitusCompletedNCT00299871Phase 2

← Lixisenatide overview